TG Therapeutics, Inc. Provides Business Update and Reports Second Quarter 2018 Financial Results
August 07, 2018 16:00 ET
|
TG Therapeutics, Inc.
NEW YORK, Aug. 07, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ended June 30, 2018 and recent company developments. ...
TG Therapeutics and Novimmune SA Announce Global Agreement for Development and Commercialization of a Novel Anti-CD47/ Anti-CD19 Bispecific Antibody
June 20, 2018 07:30 ET
|
TG Therapeutics, Inc.
NEW YORK, June 20, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX) and Novimmune SA, today announced that the companies have entered into an exclusive global agreement to collaborate on...
Interleukin-6 (IL-6) Inhibitors Therapeutics Pipeline Driven by Positive Clinical Results of Drug Candidates: P&S Market Research
February 06, 2018 04:30 ET
|
P&S Market Research
NEW YORK, Feb. 06, 2018 (GLOBE NEWSWIRE) -- According to a new research report titled "Interleukin-6 (IL-6) Inhibitors Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent,...
Shire Expands Broad Monoclonal Antibody Research Platform, Enters License Agreement for Novimmune Bi-specific Antibody
July 18, 2017 07:01 ET
|
Shire Pharmaceuticals Group
Shire Expands Broad Monoclonal Antibody Research Platform, Enters License Agreement for Novimmune Bi-specific Antibody Shire obtains worldwide license to pursue development and...
Global Bispecific Antibody Market & Clinical Pipeline Insight 2020
August 11, 2016 04:38 ET
|
Research and Markets
Dublin, Aug. 11, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Bispecific Antibody Market & Clinical Pipeline Insight 2020" drug...
Novimmune's NI-0501 Granted Breakthrough Therapy Designation by US FDA for Treatment of Patients With Primary Hemophagocytic Lymphohistiocytosis (HLH)
March 16, 2016 09:00 ET
|
Novimmune SA
GENEVA, SWITZERLAND--(Marketwired - Mar 16, 2016) - Novimmune, a Swiss biotech company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation...
Novimmune Completes CHF30 Million ($29.8 Million) Funding Round With Existing Shareholders
January 11, 2016 09:00 ET
|
Novimmune SA
GENEVA, SWITZERLAND--(Marketwired - Jan 11, 2016) - Novimmune, a Swiss biotech company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory and...
Change of Leadership at Novimmune S.A.
December 21, 2015 09:00 ET
|
Novimmune SA
GENEVA, SWITZERLAND--(Marketwired - Dec 21, 2015) - The Board of Directors at its meeting of December 16, 2015 appointed Ed Holdener as Chief Executive Officer of the Company, effective...
Novimmune Abstract Selected for the "Best of ASH" at the 2015 Annual Meeting of the American Society of Hematology (ASH)
December 15, 2015 09:00 ET
|
Novimmune SA
GENEVA, SWITZERLAND--(Marketwired - Dec 15, 2015) - Novimmune, a privately held, Swiss biotech company focused on the discovery and development of antibody-based drugs for the targeted treatment of...
Novimmune's Experimental Drug Selected for Oral Presentation at 2015 Annual Meeting of the American Society of Hematology (ASH)
December 01, 2015 09:00 ET
|
Novimmune
GENEVA, SWITZERLAND--(Marketwired - Dec 1, 2015) - Novimmune, a Swiss biotech company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory and...